Anti-MELTF / Melanotransferrin / MFI2

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. MELTF antibody detects Melanotransferrin, a cell-surface glycoprotein related to the transferrin family that participates in iron binding and transport. The UniProt recommended name is Melanotransferrin (MELTF), also known as melanoma-associated antigen p97, melanotransferrin precursor, or MAP97. MELTF was initially identified as a melanoma-associated antigen but is now recognized as a multifunctional iron-binding protein expressed in both normal and malignant cells.MELTF antibody targets a glycosylphosphatidylinositol (GPI)-anchored membrane protein of approximately 80 kDa that facilitates cellular iron uptake independent of the classical transferrin receptor pathway. It is expressed in the placenta, intestine, and brain capillaries, where it contributes to iron delivery across epithelial and endothelial barriers. In cancer biology, MELTF is overexpressed in melanomas, glioblastomas, and certain epithelial tumors, where it supports tumor cell proliferation and survival under low-iron conditions. Elevated MELTF expression is associated with increased metastatic potential and angiogenesis through modulation of iron availability.The MELTF antibody is useful in identifying tumor-associated expression and studying iron metabolism mechanisms distinct from transferrin receptor 1 (TFRC) or 2 (TFR2). Structurally, MELTF shares domain homology with transferrins, including two lobes capable of binding ferric iron, but differs by being GPI-anchored rather than secreted. The MELTF gene is located on chromosome 3q13.31 and encodes a 738-amino acid protein that undergoes glycosylation and cleavage to form the mature membrane-associated form. Its regulation is influenced by iron status, hypoxia-inducible factors (HIFs), and oncogenic signaling pathways such as MAPK and PI3K/AKT.Recent studies indicate MELTF may function in neuroprotection by mediating iron uptake in the blood-brain barrier, and mutations or autoantibodies to MELTF have been linked to neurodegenerative disorders. MELTF antibody detection in immunohistochemistry and flow cytometry enables quantification of cell-surface expression, while western blotting reveals glycosylated isoforms. MELTF also plays roles in embryonic development, wound healing, and immune modulation by regulating local iron concentrations.As an iron-binding antigen with diagnostic and therapeutic potential, MELTF antibody supports research in oncology, neurobiology, and iron transport regulation. NSJ Bioreagents provides validated antibodies suitable for detection in human, mouse, and rat tissues, optimized for cancer biomarker and transport studies.